A small molecule antagonist compound having a toll-like receptor 3/7/8/9 inhibitory function and its use in inhibiting TLR7, TLR8, TLR9 and TLR3 are disclosed. A novel compound expressed by TAC5 and TAC5-a, TAC5-c, TAC5-d or TAC5-e which are derivatives thereof not only prevents TNFα secretion, NFkB activation, IkB degradation and MAPKs phosphorylation induced by poly(I:C) (TLR3 agonist), IMQ (TLR7 agonist), CL075 (TLR7/8 agonist), R848 (TLR7/8 agonist), TL8 (TLR8 agonist) or CpG ODN (TLR9 agonist), but also inhibits generation of inflammatory cytokine, and thus is highly advantageous for preventive or therapeutic use for TLR3/7/8/9-related autoimmune diseases and inflammatory diseases including systemic lupus erythematosus, psoriasis and the like.
揭示了一种具有Toll样受体3/7/8/9抑制功能的小分子拮抗剂化合物及其在抑制TLR7、TLR8、TLR9和TLR3中的应用。由TAC5和TAC5-a、TAC5-c、TAC5-d或TAC5-e表达的新化合物,它们是其衍
生物,不仅可以预防由poly(I:C)(TLR3激动剂)、IMQ(TLR7激动剂)、CL075(TLR7/8激动剂)、R848(TLR7/8激动剂)、TL8(TLR8激动剂)或CpG ODN(TLR9激动剂)诱导的TNFα分泌、NFkB激活、IkB降解和
MAPKs
磷酸化,而且还抑制炎性细胞因子的生成,因此非常适用于预防或治疗与TLR3/7/8/9相关的自身免疫疾病和炎症性疾病,包括系统性红斑狼疮、
银屑病等。